Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome

The aim of our trial was to evaluate the prognostic significance of qualitative ctDNA analysis on different stages of EGFR mutated non-small cell lung cancer (NSCLC) treatment.We included 99 patients amendable for the first line treatment with either gefitinib/erlotinib (n = 87), afatinib (n = 10) o...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: F.V. Moiseenko, N.M. Volkov, A.S. Zhabina, M.L. Stepanova, N.A. Rysev, V.V. Klimenko, A.V. Myslik, E.V. Artemieva, V.V. Egorenkov, N.H. Abduloeva, A.O. Ivantsov, E.S. Kuligina, E.N. Imyanitov, V.M. Moiseyenko
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2022-01-01
Edice:Cancer Treatment and Research Communications
Témata:
NSCLC
EGFR
Targeted therapy
ctDNA
Prognosis
On-line přístup:http://www.sciencedirect.com/science/article/pii/S2468294222000132
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky